$1.19 Billion is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 116 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PFE | New | PFIZER INC | $47,592,000 | – | 1,106,528 | +100.0% | 4.00% | – |
| BMY | New | BRISTOL-MYERS SQUIBB COcall | $29,585,000 | – | 500,000 | +100.0% | 2.49% | – |
| PANW | New | PALO ALTO NETWORKS INC | $14,849,000 | – | 31,000 | +100.0% | 1.25% | – |
| BMRN | New | BIOMARIN PHARMACEUTICAL INC | $11,518,000 | – | 149,017 | +100.0% | 0.97% | – |
| ALT | New | ALTIMMUNE INCcall | $11,310,000 | – | 1,000,000 | +100.0% | 0.95% | – |
| New | WIX COM LTDnote 8/1 | $10,722,000 | – | 11,100,000 | +100.0% | 0.90% | – | |
| IMTX | New | IMMATICS N.V | $10,401,000 | – | 800,043 | +100.0% | 0.87% | – |
| New | OMEGA THERAPEUTICS INC | $9,952,000 | – | 527,948 | +100.0% | 0.84% | – | |
| NKE | New | NIKE INCcl b | $9,440,000 | – | 65,000 | +100.0% | 0.79% | – |
| ADSK | New | AUTODESK INC | $7,842,000 | – | 27,500 | +100.0% | 0.66% | – |
| CLDX | New | CELLDEX THERAPEUTICS INC NEW | $7,037,000 | – | 130,330 | +100.0% | 0.59% | – |
| New | OUTBRAIN INC | $6,382,000 | – | 431,194 | +100.0% | 0.54% | – | |
| BCAB | New | BIOATLA INC | $6,309,000 | – | 214,300 | +100.0% | 0.53% | – |
| ZEN | New | ZENDESK INC | $6,275,000 | – | 53,910 | +100.0% | 0.53% | – |
| PNT | New | POINT BIOPHARMA GLOBAL INC | $5,684,000 | – | 739,190 | +100.0% | 0.48% | – |
| CALX | New | CALIX INC | $5,204,000 | – | 105,290 | +100.0% | 0.44% | – |
| New | CARIBOU BIOSCIENCES INC | $4,774,000 | – | 200,000 | +100.0% | 0.40% | – | |
| FOLD | New | AMICUS THERAPEUTICS INC | $4,691,000 | – | 491,159 | +100.0% | 0.39% | – |
| PTGX | New | PROTAGONIST THERAPEUTICS INCcall | $4,430,000 | – | 250,000 | +100.0% | 0.37% | – |
| IS | New | IRONSOURCE LTD | $3,990,000 | – | 367,070 | +100.0% | 0.34% | – |
| ALGS | New | ALIGOS THERAPEUTICS INC | $3,865,000 | – | 249,197 | +100.0% | 0.32% | – |
| DVAX | New | DYNAVAX TECHNOLOGIES CORP | $3,820,000 | – | 198,880 | +100.0% | 0.32% | – |
| IMUX | New | IMMUNIC INC | $3,450,000 | – | 389,812 | +100.0% | 0.29% | – |
| QURE | New | UNIQURE NVcall | $3,201,000 | – | 100,000 | +100.0% | 0.27% | – |
| LESL | New | LESLIES INC | $3,081,000 | – | 150,000 | +100.0% | 0.26% | – |
| New | OTONOMO TECHNOLOGIES LTDordinary shares | $2,868,000 | – | 600,000 | +100.0% | 0.24% | – | |
| New | DICE THERAPEUTICS INC | $2,784,000 | – | 85,000 | +100.0% | 0.23% | – | |
| New | HIPPO HLDGS INC | $2,644,000 | – | 564,967 | +100.0% | 0.22% | – | |
| New | ARYA SCIENCES ACQUISITN CORP | $1,976,000 | – | 200,000 | +100.0% | 0.17% | – | |
| AMAT | New | APPLIED MATLS INC | $1,867,000 | – | 14,500 | +100.0% | 0.16% | – |
| MOLN | New | MOLECULAR PARTNERS AGads | $1,580,000 | – | 80,555 | +100.0% | 0.13% | – |
| New | ERASCA INC | $1,485,000 | – | 70,000 | +100.0% | 0.12% | – | |
| ACIU | New | AC IMMUNE SA | $812,000 | – | 121,019 | +100.0% | 0.07% | – |
| IONS | New | IONIS PHARMACEUTICALS INC | $738,000 | – | 22,000 | +100.0% | 0.06% | – |
| UPWK | New | UPWORK INC | $450,000 | – | 10,000 | +100.0% | 0.04% | – |
| IMCR | New | IMMUNOCORE HLDGS PLCads | $157,000 | – | 4,235 | +100.0% | 0.01% | – |
| LOGC | New | LOGICBIO THERAPEUTICS INC | $110,000 | – | 24,042 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
| SC 13G | 2023-08-30 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.